Tertius News is an AI-native newsroom: an AI model reads the linked source articles below and extracts what each outlet reported, so you can compare their coverage side by side. How this works →
Losing hair because of Alopecia? This Arthritis drug can help you regrow hair like never before
Newly published trial results suggest upadacitinib, a JAK inhibitor already used for arthritis and other inflammatory conditions, can help people with severe alopecia areata regrow significant scalp hair. About half of participants on the lower dose and more than half on the higher dose achieved at least 80% scalp coverage after 24 weeks, according to multiple reports.
A medication long used to treat rheumatoid arthritis and other inflammatory diseases may offer a new option for people with severe alopecia areata, according to clinical trial results published in JAMA Dermatology. The findings, reported by Medical News Today and several other outlets, suggest that upadacitinib, sold under the brand name Rinvoq, can prompt substantial hair regrowth in patients who have lost at least half of the hair on their scalp.
Alopecia areata is an autoimmune disorder in which the immune system mistakenly attacks hair follicles, leading to patchy hair loss that can progress to extensive scalp baldness and loss of eyebrows and eyelashes. The National Alopecia Areata Foundation estimates that the condition affects roughly 7 million Americans, while Medical News Today cites a global figure of about 160 million people living with the disease. There is currently no cure, and existing treatments include corticosteroids, immunotherapy, and other JAK inhibitors.
What the Trials Found
The Phase 3 clinical program enrolled nearly 1,400 adults and adolescents with severe alopecia areata, as reported by al.com and MassLive. The Times of India specifies the number as 1,399. Participants received either a 15-milligram daily dose of upadacitinib, a 30-milligram dose, or a placebo. The primary endpoint was achieving at least 80% scalp coverage after 24 weeks of treatment.
Results were consistent across reports. About 45% of patients on the 15-milligram dose reached the primary target, while approximately 55% of those on the higher dose did the same, according to al.com and MassLive. Medical News Today reports that about half on the lower dose and 54% on the higher dose achieved the same result. The Times of India says almost half on the lower dose and more than half on the higher dose reached that level, while only around 2% of placebo patients did. Complete scalp regrowth was reported in roughly 13% to 23% of patients at 24 weeks, depending on dosage, according to MassLive. The Times of India adds that more than a third of those on the lower dose and nearly half on the higher dose achieved at least 90% scalp coverage.
Improvements were not limited to the scalp. Some participants experienced better eyebrow and eyelash growth, as noted by MassLive, Medical News Today, and The Times of India. The Times of India also reports that responses continued to improve through one year of treatment.
How the Drug Works
Upadacitinib is a Janus kinase (JAK) inhibitor, a class of drugs that blocks enzymes involved in immune signaling. By interfering with this pathway, the drug appears to stop the immune attack on hair follicles, according to al.com and MassLive. The medication is already approved by the U.S. Food and Drug Administration for rheumatoid arthritis, Crohn's disease, and ulcerative colitis, and is also used for atopic dermatitis, as noted by Medical News Today.
The drug is currently under FDA review as a potential treatment for severe alopecia areata, and it has already been approved in the European Union for this condition, according to MassLive and Medical News Today.
Expert Perspectives
Medical News Today quotes Arash Mostaghimi, MD, MPH, vice chair of clinical trials and innovation in the Department of Dermatology at Brigham and Women's Hospital and associate professor at Harvard Medical School, who is the first author of the study. Mostaghimi described alopecia areata as "an autoimmune condition causing hair loss that carries a profound psychosocial burden for patients" and noted that "many individuals still do not respond sufficiently to existing therapies." He said developing new medications is "critical to expanding effective options for these patients."
The same article includes comments from Joseph W. Fakhoury, MD, a dermatologist at Henry Ford Hospital and a spokesdoctor for the National Alopecia Areata Foundation, who said the results are encouraging.
Considerations and Caveats
The Times of India emphasizes that upadacitinib is not a treatment for common hair thinning or receding hairlines, which have different causes. Side effects reported during the trials included acne, colds, and upper respiratory infections, according to the same outlet. The Times of India also warns against misuse of the drug, stressing that it should only be used under medical supervision.
While the results are promising, the drug's approval status in the U.S. remains pending. As reported by MassLive, upadacitinib is under FDA review for severe alopecia areata, and the European approval came earlier this year.
Framing: Emphasizes the drug's brand name (Rinvoq) and 'strong hair regrowth results' as a study outcome; omits that it's an arthritis drug already used for other conditions. — Hopeful and measured; phrases like 'may offer new hope' and 'notable' results, but avoids hype.
Facts Included:
Upadacitinib (Rinvoq) is a JAK inhibitor approved for rheumatoid arthritis, Crohn's disease, and ulcerative colitis.
Phase 3 trial enrolled nearly 1,400 adults and adolescents with severe alopecia areata.
Doses: 15 mg, 30 mg, or placebo.
Primary endpoint: at least 80% scalp coverage after 24 weeks.
Results: ~45% on 15 mg, ~55% on 30 mg achieved primary endpoint; small percentage on placebo.
Complete scalp regrowth in 13-23% at 24 weeks.
Improvements in eyebrows and eyelashes.
Upadacitinib under FDA review; approved in EU earlier this year.
Alopecia areata affects ~7 million Americans (NAAF estimate).
Condition can have emotional and psychological effects, especially in children/adolescents.
Framing: Headline simplifies to 'Rheumatoid arthritis drug may treat hair loss', focusing on repurposing rather than the brand name. — Professional and expert-driven; quotes physicians, emphasizes clinical significance and quality of life.
Facts Included:
About 160 million people worldwide live with alopecia areata.
No cure for alopecia areata.
Current treatments include corticosteroids, immunotherapy, and JAK inhibitors.
Study published in JAMA Dermatology, first author Arash Mostaghimi, MD, MPH, of Brigham and Women's Hospital and Harvard Medical School.
Randomized phase 3 trial with almost 1,400 participants (adults and adolescents) with severe alopecia areata.
Received 15 mg or 30 mg upadacitinib; used for rheumatoid arthritis, ulcerative colitis, Crohn's disease, and atopic dermatitis.
About half on 15 mg and 54% on 30 mg achieved at least 80% scalp coverage at 24 weeks.
Participants had improved eyebrows/eyelashes and felt better emotionally and socially.
Upadacitinib already approved for severe alopecia in Europe; under FDA review.
Comments from Joseph W. Fakhoury, MD, dermatologist at Henry Ford Hospital and NAAF spokesdoctor.
Framing: Headline uses a rhetorical question and hyperbolic phrasing ('like never before'), emphasizing the surprise that an arthritis drug can help; omits the drug's name and trial specifics. — Informal and cautious; uses colloquial language ('something quite different', 'noticeable') and explicitly warns against misuse.
Facts Included:
Upadacitinib is a JAK inhibitor used for arthritis.
Two Phase III trials included 1,399 people with severe alopecia areata.
Doses: 15 mg, 30 mg, or placebo.
After 24 weeks, ~50% on 15 mg and more than half on 30 mg achieved at least 80% scalp coverage.
Placebo response: around 2%.
More than a third on lower dose, nearly half on higher dose achieved at least 90% scalp coverage.
Improvements in eyebrow and eyelash growth.
Alopecia areata is an autoimmune disease where immune system attacks hair follicles.
Drug blocks JAK enzymes involved in immune signaling.
Side effects: acne, colds, upper respiratory infections.
Not a treatment for common hair thinning or receding hairlines.
Each row is one claim, attributed to the outlet whose wording states it most clearly. Confidence rates how directly the source text states the claim — explicit and unhedged rates high; hedged, pieced-together, or internally inconsistent statements rate lower. It does not measure whether the claim is true. Status counts the distinct outlets we found asserting it — so a single-source claim can still show high confidence, and a multi-source claim can show medium. Every one of those outlets is named beside the status, so you can check the count against the list. For claims extracted before we began storing that list, the row says so: it names the outlet the claim is quoted from and states that we have not recorded which outlets backed it. Outlets wrote at different times, so a figure that evolves — a casualty count, for example — can legitimately differ between rows; check the "as of" time next to each claim's source.
Claim
Confidence
Status
ClaimUpadacitinib (Rinvoq) is a JAK inhibitor approved by the FDA for rheumatoid arthritis, Crohn's disease, and ulcerative colitis.
ClaimThe study was published in JAMA Dermatology and first author is Arash Mostaghimi, MD, MPH, of Brigham and Women's Hospital and Harvard Medical School.
7 outlets · 7 articles consulted: al.com, MassLive, Medical News Today, M Live Michigan, nj.com, Mechanicsburg Patriot News, The Times of India33 claims extractedVersion 2Written 2026-08-24